Paclitaxel as HIPEC-Drug after Surgical Cytoreduction for Ovarian Peritoneal Metastases: A Randomized Phase III Clinical Trial (HIPECOVA)

Paclitaxel as HIPEC-Drug after Surgical Cytoreduction for Ovarian Peritoneal Metastases: A Randomized Phase III Clinical Trial (HIPECOVA)

Multidisciplinary strategies have transformed the management of advanced ovarian cancer. We aimed to evaluate the effectiveness of paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) following surgical cytoreduction for ovarian peritoneal metastases in a randomized phase III trial conduc...

Full description

Bibliographic Details
Main Authors: Pedro Villarejo Campos, Susana Sánchez García, Mariano Amo-Salas, Esther García Santos, Carlos López de la Manzanara, Ana Alberca, David Padilla-Valverde, Francisco Javier Redondo Calvo, Jesús Martín
Format: Article
Language:English
Published: MDPI AG 2024-01-01
Series:Current Oncology
Subjects:
advanced or recurrent ovarian cancer
HIPEC
paclitaxel
cytoreduction
peritoneal metastases
peritoneal surface disease severity score
Online Access:https://www.mdpi.com/1718-7729/31/2/48

Similar Items

Similar Items